Johnson & Johnson Inc, whose Janssen business unit is active throughout Europe, is to split into two separate companies by spinning off its consumer healthcare products division from its more lucrative pharmaceuticals and medical devices business. Announced on 12 November, the demerger is expected to be completed in 18 to 24 months.
